20/20 Biolabs, Inc. (AIDX) Fair Value 2026

AIDX · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.7 /10

32 fundamental signals · 10 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-13, 20/20 Biolabs, Inc. (AIDX) trades at $0.57, approximately 83% above CirclFi’s Bayesian DCF fair value of $0.31. QOC: 5.7/10. 10/13 models active.

Key Facts

Ticker
AIDX
Price
$0.57
Quality Score
5.7/10
Value Trap Risk
—/100
Models Active
10/13
Last Updated
Strength: First Chicago suggests +5.7% upside with 20% confidence
Risk: Majority of models suggest overvaluation

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($0.57)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.31 -45.4%
Earnings Power Value
Low Conviction
 $0.51 -10.0%
CUCE Ensemble
Low Conviction
 $0.49 -13.6%
First Chicago
Medium Conviction
 $0.60 +5.7%

Unlock the Full Matrix

Access 6 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is 20/20 Biolabs, Inc. (AIDX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, 20/20 Biolabs, Inc.'s intrinsic value is estimated at a composite fair value of $0.47. Trading at $0.57, the stock is approaching fair value or slight overvaluation (implied return of -17.9%), as 6 of 10 models suggest limited further upside. The most optimistic model, EROIC, places fair value at $0.72 (+26.2%), while ML-RIV — the most conservative — estimates $0.07 (-87.7%). This +113.9% gap reflects genuine analytical uncertainty about 20/20 Biolabs, Inc.'s intrinsic worth.

What Do the Models Say About AIDX?

10 of 13 models are currently active for AIDX. Of these, 4 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates AIDX's intrinsic value at $0.31, implying -45.4% downside from the current price. See which stocks rank higher →

How Does AIDX Rank in Medical Devices?

Among 10 Medical Devices stocks, AIDX ranks #5 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.

20/20 Biolabs, Inc.'s positioning within the Medical Devices segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.

Is AIDX a Value Trap?

The Value Trap algorithm is not active for AIDX. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for 20/20 Biolabs, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, 20/20 Biolabs, Inc. earns a quality score of 5.7/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +113.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AIDX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across AIDX's 10 active models, average confidence is 20%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy 20/20 Biolabs, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

8 related Medical Devices stocks with 13-model coverage

ABTAbbott LaboratoriesQOC 10.0AORTArtivion, Inc.QOC 7.5AHCOAdaptHealth Corp.QOC 7.2APYXApyx Medical CorporationQOC 6.4ADGMAdagio Medical Holdings, IncQOC 5.7AEMDAethlon Medical, Inc.QOC 4.9AMIXAutonomix Medical, Inc.QOC 4.1ARAYAccuray IncorporatedQOC 3.4

Read investment analysis: ABT · AORT · AHCO · APYX · ADGM

Frequently Asked Questions About 20/20 Biolabs, Inc.

What is 20/20 Biolabs, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, 20/20 Biolabs, Inc. (AIDX) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.31. The Quality of Company score is 5.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AIDX overvalued or undervalued right now?

At $0.57, 4 of 10 active models suggest AIDX may be undervalued, while 6 indicate potential overvaluation. The assessment depends on which methodology best fits 20/20 Biolabs, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 5.7 mean for AIDX?

20/20 Biolabs, Inc.'s QOC of 5.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on AIDX?

CirclFi analyzes AIDX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is AIDX a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for AIDX at this time. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on AIDX.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access